The trademark application novo nordisk was filed by Novo Nordisk A/S, a corporation established under the laws of the Kingdom of Denmark (the "Applicant"). The application was published for oppositions on May 28, 2020, and it was registered by office on September 7, 2020 without any oppositions.
The application was filed in Danish (English was selected as the second language).
Goods And Services
The mark was filed in class 1 with following description of goods:
Chemical preparations for use in industry
Chemical additives
Chemical additives for use in the manufacture of pharmaceuticals, cosmetics, hair lotions, disinfectants
Chemical diagnostic reagents for industrial use
Chemical preparations for use in the oil industry.
The mark was filed in class 5 with following description of goods:
Pharmaceutical preparations for the treatment of diabetes and obesity
Pharmaceutical preparations for haemostasis management and for the treatment of sickle cell disease
Pharmaceutical preparations for the treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease
Pharmaceutical preparations for hormone therapy and stem cells for medical purposes
Delivery devices containing the abovementioned products
Chemical preparations for use in medical devices.
The mark was filed in class 9 with following description of goods:
Electronic publications, namely, leaflets, books, booklets, handouts, magazines as well as medical, instructional and teaching material in the field of diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment
Electronic reports featuring results from clinical trials and studies in the field of prevention and treatment of diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment
Software applications for use with mobile devices for monitoring and the management of diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment
Computer hardware and software, for use with medical injection devices for collecting, transmitting, and displaying medical data
Medical software for the management of diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment
Software intended for medical purposes that perform these purposes without being part of a hardware medical device.
The mark was filed in class 10 with following description of goods:
Medical and surgical apparatus and instruments, namely, hypodermic syringes and pens
Medical apparatus and instruments for reconstitution and injection of pharmaceutical preparations
Medical apparatus and instruments, namely, injection devices for administration of pharmaceutical preparations, medical infusion pumps, infusion pump controllers, adhesive infusion devices
Digitally connected medical devices for monitoring the dispensation of pharmaceutical preparations for use in connection with the management of diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment
Medical and surgical apparatus and instruments, namely, injection devices for the administration of pharmaceutical preparations and the wireless transmission of medical data in connection with the management of diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment
Medical devices, namely, automatic needle insertion devices, protection caps for hypodermic syringes and medical pens
Needles for injections
Cartridges and carpules for administration pharmaceutical preparations.
The mark was filed in class 41 with Educational services, namely, organizing and conducting educational programmes, coaching and training services for patients and healthcare professionals related to management of diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment and arranging and conducting of conferences, congresses, seminars, symposiums and workshops related to the management of diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment..
The mark was filed in class 42 with following description of goods:
Providing scientific information on diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment
Providing websites and mobile apps featuring technology that enables users to record, track, and generate reports regarding the condition, treatment and the management of diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment
Computer services, namely providing access to data concerning medical analysis and management of diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment.
The mark was filed in class 44 with Providing medical services via websites and mobile apps for the management of diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment and providing medical information and medical counselling the management of diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment..